Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.41 |
| ▸ | GRM5 | P41594 | 3/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.37 |
| ▸ | KIT | P10721 | 5/20 | 0.35 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.34 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.34 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.34 |
| ▸ | PLAT | P00750 | 4/20 | 0.34 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22357930 | 0.84 | NR1H4 (0.58) | NR1H4GRM5PIK3CDKITTLR9 | |
| SCHEMBL22357924 | 0.82 | NR1H4 (0.51) | NR1H4GRM5PIK3CDTLR9TLR8 | |
| SCHEMBL20116695 | 0.81 | GRM5 (0.35) | NR1H4GRM5PIK3CDKITBRD4 | |
| SCHEMBL22358136 | 0.80 | NR1H4 (0.44) | NR1H4GRM5PIK3CDTLR9TLR8 | |
| SCHEMBL20117198 | 0.78 | NPC1 (0.54) | NR1H4GRM5PIK3CD | |
| SCHEMBL22357935 | 0.77 | PIK3CD (0.36) | NR1H4GRM5PIK3CDKITBRD4 | |
| SCHEMBL22357941 | 0.76 | NR1H4 (0.39) | NR1H4GRM5KITTLR9TLR8 | |
| SCHEMBL22357943 | 0.76 | NR1H4 (0.53) | NR1H4GRM5KITTLR9TLR8 | |
| SCHEMBL22358473 | 0.76 | NR1H4 (0.58) | NR1H4KITTLR9TLR8TLR7 | |
| SCHEMBL20116409 | 0.76 | GRM5 (0.43) | NR1H4GRM5PIK3CDPTGER3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11873298-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2024-01-16 | — | — | US | disclosed |
| US-11873298-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2024-01-16 | — | — | US | disclosed |
| US-20200262828-A1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2020-08-20 | — | — | US | disclosed |
| WO-2019209948-A9 | COMPOUNDS AND USES THEREOF | YUMANITY THERAPEUTICS, INC. (US) | 2020-01-02 | — | — | WO | disclosed |
| WO-2019018795-A1 | COMPOUNDS AND USES THEREOF | YUMANITY THERAPEUTICS (US) | 2019-01-24 | — | — | WO | disclosed |
| WO-2018081167-A1 | COMPOUNDS AND USES THEREOF | YUMANITY THERAPEUTICS (US) | 2018-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11873298-B2 | Compounds and uses thereof | NLN, ACHE, CLN6 | NR1H4 1341/4885GRM5 68/4885PIK3CD 3927/4885 |
| US-20200262828-A1 | COMPOUNDS AND USES THEREOF | NLN, ACHE, CLN6 | NR1H4 1341/4885GRM5 68/4885PIK3CD 3927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.